Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypoglycaemic Response to Insulin 287 Overdosing in T2D
NCT03945656Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin icodec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Clinically significant hypoglycaemia (Double dose). Started May 2019; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03945656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945656.